Roslyn Wallace

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma

C. Owen, Xue Bai, Serigne Lo et al. · Annals of Oncology · 2021 · 184 citations · Full text

Medicine, Immunology, Oncology +14

LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).

Shahneen Sandhu, Anthony M. Joshua, Louise Emmett et al. · Journal of Clinical Oncology · 2023 · 78 citations

Medicine, Nuclear Medicine, Pharmacology +17

FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment

Amir Iravani, Medhat Osman, Alison M. Weppler et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 70 citations

Medicine, Nuclear Medicine, Oncology +17

The relationship between tumour site, clinicopathological characteristics and cancer‐specific survival in patients undergoing surgery for colorectal cancer

Arfon Powell, Roslyn Wallace, Ruth F. McKee et al. · Colorectal Disease · 2012 · 63 citations

Medicine, Oncology, Surgery +16

PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).

Shahneen Sandhu, Anthony M. Joshua, Louise Emmett et al. · Journal of Clinical Oncology · 2022 · 60 citations

Medicine, Oncology, Pharmacology +17